Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARα-positive leukemic stem cells

Haematologica

Volumn 92, Issue 3, 2007, Pages 323-331

  Zheng, Xiaomin ^a   Seshire, Anita ^a   Rüster, Brigitte ^a   Bug, Gesine ^a   Beissert, Tim ^a   Puccetti, Elena ^a   Hoelzer, Dieter ^a   Henschler, Reinhard ^a   Ruthardt, Martin ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic; Leukemic stem cell

Indexed keywords

ARSENIC TRIOXIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETROVIRUS VECTOR; ANTINEOPLASTIC AGENT; ATAXIN 1; ATAXIN-1; GROWTH INHIBITOR; HYBRID PROTEIN; NERVE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC TRANSDUCTION; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CELL DIVISION; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; PATHOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 34247599900     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10541     Document Type: Article

References (31)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
2. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.
3. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004; 23:7178-87.
4. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, et al. {gamma}-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004;22:22.
5. Melnick A, Licht JD. Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
6. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
7. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001;20:7140-5.
8. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003;8:132-40.
9. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, et al. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 2005;105: 1366-7.
10. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990;76:1758-64.
11. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74:423-31.
12. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor a mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-8.
13. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995;85:1083-94.
14. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RARα) and PLZF-RARα fusion proteins on retinoic acid signalling. Mol Cell Biol 1997;17:4859-69.
15. Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) (q23;q21) APL patient. Oncogene 1999;18:1113-8.
16. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002;16: 1896-905.
17. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005; 65: 2537-41.
18. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994;367:645-8.
19. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22.
20. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
21. Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409-13.
22. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004;23:7210-22.
23. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-33.
24. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101:781-6.
25. De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005;65:1505-13.
26. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61:2-7.
27. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005;104:2717-25.
28. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759-67.
29. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17: 131-4.
30. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627-32.
31. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002;7 Suppl 1:14-9.